D

    DAWN (DAWN)

    Official site

    BIOTECHNOLOGY

    $21.53
    +0.00 (+0.00%)

    Last updated: Apr 23, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(12/20)
    Avg Surprise
    -59.02%

    Upcoming Estimates

    Period ending Mar 31, 2026
    EPS Consensus$-0.17
    Range$-0.28 - $-0.09
    6 analysts
    EPS RevisionsNo revisions (7d)
    1
    3
    30d
    EPS Estimate Drift
    90d ago$-0.19-10.5%
    60d ago$-0.19-10.5%
    30d ago$-0.16+5.8%
    7d ago$-0.15+12.8%
    Current$-0.17
    Revenue Consensus
    $54M
    Range$48M - $60M
    9 analysts
    Period ending Jun 30, 2026
    EPS Consensus$-0.16
    Range$-0.28 - $-0.03
    6 analysts
    EPS RevisionsNo revisions (7d)
    1
    3
    30d
    EPS Estimate Drift
    90d ago$-0.14+8.2%
    60d ago$-0.14+8.2%
    30d ago$-0.14+10.3%
    7d ago$-0.13+15.4%
    Current$-0.16
    Revenue Consensus
    $57M
    Range$53M - $63M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26EST
    		-$-0.16---
    Mar 26EST
    		-$-0.17---
    Dec 25
    Reported Feb 24
    		$-0.21$-0.19-8.81%Miss+66.7%
    Sep 25
    Reported Nov 4
    		$-0.19$-0.29+34.48%Beat-150.0%
    Jun 25
    Reported Aug 5
    		$-0.29$-0.35+17.38%Beat-480.0%
    Mar 25
    Reported May 6
    		$-0.35$-0.42+16.67%Beat+51.4%
    Dec 24
    Reported Feb 25
    		$-0.63$-0.46-36.22%Miss+1.6%
    Sep 24
    Reported Oct 30
    		$0.38$-0.32+220.41%Beat+170.4%
    Jun 24
    Reported Jul 30
    		$-0.05N/A+93.33%Beat+91.8%
    Mar 24
    Reported May 6
    		$-0.72$-0.66-9.09%Miss-22.0%
    Dec 23
    Reported Feb 26
    		$-0.64$-0.58-10.34%Miss-14.3%
    Sep 23
    Reported Nov 6
    		$-0.54$-0.60+10.00%Beat-1.9%
    Jun 23
    Reported Aug 7
    		$-0.61$-0.61+0.00%Beat-1.7%
    Mar 23
    Reported May 1
    		$-0.59$-0.59+0.00%Beat-22.9%
    Dec 22
    Reported Mar 6
    		$-0.56$-0.57+1.75%Beat-55.6%
    Sep 22
    Reported Nov 7
    		$-0.53$-0.53+0.00%Beat-60.6%
    Jun 22
    Reported Aug 4
    		$-0.60$-0.49-22.45%Miss+88.1%
    Mar 22
    Reported May 12
    		$-0.48$-0.38-26.32%Miss+28.4%
    Dec 21
    Reported Mar 7
    		$-0.36$-0.36+0.00%Beat+94.0%
    Sep 21
    Reported Nov 8
    		$-0.33$-0.28-17.86%Miss+50.9%
    Jun 21
    Reported Aug 10
    		$-5.04$-0.31-1525.81%Miss-
    Mar 21
    Reported May 27
    		$-0.67N/A+82.46%Beat-
    Dec 20
    Reported Mar 31
    		$-5.99$0.00N/AMiss-
    Dec 19
    Reported Mar 31
    		$-0.67$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$21.48
    SMA 20$21.46
    SMA 50$18.21
    SMA 200$10.72
    EMA 10$21.48
    EMA 20$21.13
    EMA 50$18.70
    EMA 200$12.63

    MACD

    Line: 0.74Signal: 1.00Hist: -0.26

    ADX

    ADX: 65.7+DI: 53.0-DI: 9.7

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down4.0
    PSAR$21.43

    Bollinger Bands

    Upper Band$21.53
    Lower Band$21.39
    %B Position65%(Middle)
    Band Width1.00

    RSI (14-Day)

    Overbought
    80.3

    Momentum Oscillators

    Stoch %K96.3
    Stoch %D91.3
    Williams %RN/A
    ROC (10d)0.2%
    Momentum0.05
    CCI (20d)191.3
    MFI (14d)65.2

    Volatility Measures

    ATR (14d)$0.16(0.7%)
    StdDev (20d)0.03
    Hist Vol1.5%(Low)

    Volume Flow

    VWAP$21.53
    OBV126.4M
    AD Line49.2M
    CMF (20d)0.078

    Volume Metrics

    Avg Vol (20d)1.5M
    Vol RatioN/A
    VWMA (20d)$21.46

    Pivot Points

    R3$21.58
    R2$21.56
    R1$21.54
    Pivot Point$21.52
    S1$21.50
    S2$21.48
    S3$21.46

    Advanced Oscillators

    TSI61.68
    Ultimate Osc58.6
    KST264.95

    Financial Data

    QuarterDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total Revenue$53.72M$39.80M$33.91M$30.76M$29.21M$93.76M$8.19M$0$560,000$0$0$0
    Cost of Revenue$6.08M$4.48M$3.77M$2.88M$2.98M$1.59M$707,000$116,000$103,000$99,000$92,000$89,000
    Gross Profit$47.64M$35.31M$30.14M$27.88M$26.23M$92.17M$7.49M$-116,000$-103,000$-99,000$-92,000$-89,000
    Operating Expenses$75.09M$59.57M$65.12M$68.94M$91.56M$62.53M$122.29M$66.65M$59.41M$51.34M$49.16M$45.77M
    R&D$40.95M$31.42M$36.15M$39.62M$61.82M$33.56M$92.11M$40.21M$37.35M$33.16M$32.18M$27.83M
    SG&A$34.15M$28.15M$28.97M$29.32M$31.55M$28.97M$30.19M$26.56M$22.17M$18.27M$17.07M$18.03M
    Operating Income$-27,458,000$-24,251,000$-34,974,000$-41,067,000$-65,331,999$29.64M$-114,807,000$-66,766,999$-59,517,000$-51,438,000$-49,254,000$-45,855,000
    Interest Income$4.15M$4.56M$4.67M$5.09M$6.05M$5.32M$0$0$0$5.29M$3.41M$3.47M
    Interest Expense$0$0$0$0$0$0$0$0$3.46M$0$0$3.46M
    Income Before Tax$-23,254,000$-19,726,000$-30,322,000$-35,996,000$-59,240,000$36.16M$-2,855,000$-62,412,000$-54,511,000$-46,150,000$-45,863,000$-42,393,000
    Income Tax Expense$-1,976,000$0$0$0$6.47M$-882,000$1.55M$72,724$10.52M$-99,000$-3,406,000$-7,017,000
    Net Income$-21,278,000$-19,726,000$-30,322,000$-35,996,000$-65,714,000$37.04M$-4,407,000$-62,412,000$-54,511,000$-46,150,000$-45,863,000$-42,393,000
    EBITDA$-22,575,000$-18,787,000$-29,358,000$-35,102,000$-58,480,999$36.90M$-2,447,000$-62,295,999$-54,408,000$-46,051,000$-45,771,000$-42,304,000
    EBIT$-23,254,000$-19,726,000$-30,322,000$-35,996,000$-59,239,999$36.16M$-2,855,000$-62,411,999$-54,511,000$-46,150,000$-45,863,000$-42,393,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DAWN

    News

    Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

    Bicara Therapeutics Inc. announced the appointments of Jeremy Bender, Ph.D., MBA, and Christy Oliger to its Board of Directors. These appointments bring extensive commercial, strategic, and operational expertise to Bicara as it advances its lead program, ficerafusp alfa. Concurrently, Kiran Mazumdar-Shaw has retired from the Board, with the company acknowledging her significant contributions since its inception.

    Sahm•7/28/26•
    Neutral

    Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

    Bicara Therapeutics Inc. (Nasdaq: BCAX) has announced the appointments of Jeremy Bender, Ph.D., MBA, and Christy Oliger to its Board of Directors. These appointments bring significant experience in corporate strategy, operations, commercialization, and oncology to Bicara, which is a clinical-stage biopharmaceutical company focused on bifunctional therapies for solid tumors. Additionally, Kiran Mazumdar-Shaw has retired from the Board, and was acknowledged for her foundational contributions to the company.

    Yahoo Finance Australia•7/28/26•
    Neutral

    Day One Biopharmaceuticals updates its development pipeline, shares react to recent analyst interest

    Day One Biopharmaceuticals, a small-cap biotech focusing on targeted therapies for pediatric and adult cancers, has recently drawn attention due to pipeline updates and analyst commentary on its risk profile. The company's clinical strategy involves identifying genetically defined patient subsets and advancing candidates through early-stage trials. Despite being a smaller player, the company is being compared to more advanced peers in the NASDAQ biotech universe, with analysts highlighting the balance between scientific promise and financing risk in clinical-stage oncology.

    Ad-hoc-news.de•6/26/26•
    Somewhat-Bullish

    Day One Biopharmaceuticals Stock - Long-term oncology pipeline in focus

    Day One Biopharmaceuticals, a clinical-stage oncology company, is primarily focused on developing targeted therapies for pediatric and genomically defined cancers. With no new market-moving news, the company's long-term strategy and drug pipeline are currently in focus. Their business model relies on heavy R&D investment, multi-stage clinical trials, and aims for future revenue through drug approvals and potential partnerships.

    AD HOC NEWS•6/20/26•
    Neutral

    Day One Biopharmaceuticals Inc (DAWN) Dividends & Stock Splits: Historical Payouts and Event Timeline

    This article provides an overview of Day One Biopharmaceuticals Inc (DAWN)'s dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no recorded stock split data. The page also displays current stock information and market capitalization for DAWN.

    TradingKey•6/18/26•
    Neutral

    Frequently Asked Questions About DAWN

    Does DAWN pay dividends?
    DAWN (DAWN) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In